Metformin & Dulaglutide Interaction

Dulaglutide (a once-weekly GLP-1 receptor agonist) and metformin are a well-established combination for type 2 diabetes. Dulaglutide demonstrated cardiovascular benefit in the REWIND trial (reduction in MACE). The combination provides complementary glycemic control, meaningful weight reduction, and a low intrinsic hypoglycemia risk.

Dulaglutide activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and delay gastric emptying. Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity. No pharmacokinetic interaction has been identified between the two drugs. The complementary mechanisms lower HbA1c more effectively than either agent alone without markedly increasing hypoglycemia risk.

The AWARD clinical trial program evaluated dulaglutide in patients on background metformin, showing HbA1c reductions of 0.7–1.6% and weight loss of 1–3 kg. The REWIND trial demonstrated that dulaglutide reduced cardiovascular events in patients with type 2 diabetes who had or were at risk for cardiovascular disease, many of whom were on background metformin.

Initiate dulaglutide at 0.75 mg SC weekly. Can escalate to 1.5 mg, 3.0 mg, or 4.5 mg weekly based on tolerability and glycemic targets. Metformin dose does not require adjustment. Counsel patients on injection technique and GI side effect management.

HbA1c every 3 months until stable. Renal function annually (metformin). Body weight. GI tolerability, especially during dose escalation. Report persistent abdominal pain (potential pancreatitis signal).

If GI side effects are intolerable, an alternative GLP-1 agonist with different dosing schedules (e.g., semaglutide) or a different drug class such as an SGLT-2 inhibitor may be considered.